Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
Tonix Pharmaceuticals presented retrospective real-world claims data at the ISPOR 2026 Annual Meeting, analyzing over 261,000 U.S. adults with fibromyalgia. The study highlighted a high comorbidity burden, with 93.2% of patients having at least one related condition, and extensive healthcare resource utilization, including $29,896 in annual inpatient costs per patient.
Key figures
- Nsaid usage pct
- 43.4%
- Comorbidity rate
- 93.2%
- Opioid usage pct
- 39.4%
- Study cohort size
- 261776
- Female patient pct
- 92.1%
- Median patient age
- 53
- Antidepressant usage pct
- 48.2%
- Anxiety depression comorbidity
- 63.9%
- Annual pharmacy cost per patient
- 9453
- Annual inpatient cost per patient
- 29896
- Annual outpatient cost per patient
- 6196
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.